Patents Examined by Maryam Monshipouri
  • Patent number: 11965184
    Abstract: Engineered Cas9 systems are disclosed herein.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: April 23, 2024
    Assignee: Sigma-Aldrich Co. LLC
    Inventor: Fuqiang Chen
  • Patent number: 11959073
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: April 16, 2024
    Assignee: SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
  • Patent number: 11959112
    Abstract: Cotton-containing textiles, such as “trash” feedstock in terms of end-of-life-cotton textiles, may be used to produce sugar without the same kinds of harsh pretreatments used for other biomasses, such as corn, grass sources, or wood. Disclosed is a process for production of sugar from a cotton-containing textile waste fabric comprising optionally mechanically pretreating the cotton-containing textile, pretreating the cotton-containing textile with an acid pretreatment to form a slurry, cooling the slurry, adding at least one base to the slurry, adding at least one additional acid to the slurry to form a buffer in situ, adding a hydrolysis enzyme, and optionally filtering the slurry.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: April 16, 2024
    Assignee: COTTON INCORPORATED
    Inventors: Matthew J. Farrell, Sha Fu, Mary A. Ankeny
  • Patent number: 11952398
    Abstract: A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: April 9, 2024
    Assignee: KM Biologics Co., Ltd.
    Inventors: Kentaro Ebisu, Takashi Kai, Nozomi Matsuo
  • Patent number: 11946080
    Abstract: Disclosed herein is one or more subtilisin variants, nucleic acids encoding same, and compositions and methods related to the production and uses thereof, including one or more subtilisin variants that has improved stability and/or soil removal compared to one or more reference subtilisin.
    Type: Grant
    Filed: June 18, 2017
    Date of Patent: April 2, 2024
    Assignee: DANISCO US INC.
    Inventors: Richard R. Bott, David A. Estell, Frits Goedegebuur, Harm Mulder, Sina Pricelius
  • Patent number: 11946197
    Abstract: The present disclosure relates to a method for modifying polyester by a swelling agent combined with cutinase, belonging to the technical field of textile processing. According to the method, a phenol solution or an o-vanillin solution is used as the swelling agent to perform swelling treatment on the polyester, and combined with a Humicola insolens cutinase solution to perform hydrophilic modification on the polyester, which not only significantly improves the release amount of hydrolysates, but also reduces the fabric mass loss compared with the traditional chemical modification method.
    Type: Grant
    Filed: July 27, 2023
    Date of Patent: April 2, 2024
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Jiajia Fu, Jundan Feng, Artur Cavaco-paulo, Rong Li, Yuzheng Lu, Xinming Zheng, Ruijuan Han, Chaoran Meng
  • Patent number: 11939616
    Abstract: The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the ?(1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: March 26, 2024
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Robert Sackstein
  • Patent number: 11939613
    Abstract: The present disclosure relates to the production of cannabinoids in yeast. In as aspect there is provided a genetically modified yeast comprising: one or more GPP producing genes and optionally, one or more GPP pathway genes; two or more olivetolic acid producing genes; one or more cannabinoid precursor or cannabinoid producing genes; one or more Hexanoyl-CoA producing genes, and at least 5% dry weight of fatty acids or fats.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: March 26, 2024
    Assignee: BIOMEDICAN, INC.
    Inventors: Maxim Mikheev, Difeng Gao
  • Patent number: 11926819
    Abstract: Provided are methods of adding a polymer of non-canonical nucleotides to the 3? end of a ribonucleic acid (RNA). In certain embodiments, the methods comprise combining an RNA, a polynucleotide-3? nucleotidyl transferase, and non-canonical nucleotides, in a reaction mixture under conditions in which the polynucleotide-3? nucleotidyl transferase adds a polymer of the non-canonical nucleotides to the 3? end of the RNA. Such methods may further include analyzing the RNA using a nanopore. According to some embodiments, the methods include identifying the polymer of non-canonical nucleotides added to the 3? end of the RNA, and determining the junction between the 3? end of the RNA and the polymer of non-canonical nucleotides to identify the 3? end of the RNA. Kits that find use, e.g., in practicing the methods of the present disclosure are also provided.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 12, 2024
    Assignee: The Regents of the University of California
    Inventors: Manuel Ares, Logan Mulroney, Jenny Vo, Mark Akeson
  • Patent number: 11913033
    Abstract: The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: February 27, 2024
    Assignee: Light Bio, Inc.
    Inventor: Il'ya Viktorovich Yampol'skiy
  • Patent number: 11905541
    Abstract: The present invention is directed to methods and kits for template-free enzymatic synthesis of polynucleotides that include or enable a step of efficiently cleaving the polynucleotide products from its initiator using an endonuclease V activity and initiator with a 3?-penultimate deoxyinosine.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: February 20, 2024
    Assignee: DNA Script SAS
    Inventor: Sandrine Creton
  • Patent number: 11899021
    Abstract: Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).
    Type: Grant
    Filed: January 4, 2023
    Date of Patent: February 13, 2024
    Assignee: Promega Corporation
    Inventors: Melanie Dart, Lance P. Encell, Thomas Kirkland, Thomas Machleidt, Matthew Robers, Brock F. Binkowski, Keith Wood, Ce Shi
  • Patent number: 11891645
    Abstract: The present invention relates to serine protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease derived from a strain of Meripilus giganteus belonging to the S53 family. The varinats according to the invention have in particular increased stability, e.g., increased thermo-stability, increased specific activity, and/or increased expression levels, compared to the parent protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 6, 2024
    Assignee: NOVOZYMES A/S
    Inventors: Dorte M. K. Klitgaard, Roland Alexander Pache, Martin Gudman, Anders G. Sandström
  • Patent number: 11891634
    Abstract: Disclosed herein are systems, methods, and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 6, 2024
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Thomas J. Wandless, Ling-Chun Chen, Yusaku Miyamae
  • Patent number: 11884954
    Abstract: A protein complex based on DNA enzymes of an E family of Escherichia coli and an application thereof in artificial protein scaffolds are provided. The protein complex includes one or more of interaction pairs formed by a CL2 protein and an Im2 protein, a CL7 protein and an Im7 protein, a CL8 protein and an Im8 protein, or a CL9 protein and an Im9 protein. By protein engineering of a carboxyl terminus DNase domain of the DNA enzymes CE2, CE7, CE8 and CE9, mutants that lose DNA enzyme activity but still retain the ultra-high affinity with the corresponding Im protein are obtained, and protein interaction pairs CL2/Im2, CL7/Im7, CL8/Im8 and CL9/Im9 are constructed. These protein interaction pairs have properties of heat resistance, high affinity, high specificity, small molecular weight, fast assembly speed, etc. Based on this, an artificial protein scaffold is constructed for the construction of artificial multienzyme complexes.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: January 30, 2024
    Assignee: Hubel University
    Inventors: Lixin Ma, Chao Zhai, Jun Yang, Fei Wang
  • Patent number: 11884927
    Abstract: This invention provides compositions and methods for providing high product yield of transgenes expressed in cyanobacteria and microalgae.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of California
    Inventors: Anastasios Melis, Cinzia Formighieri
  • Patent number: 11884928
    Abstract: The invention provides methods for genetically engineering Kluyveromyces. The methods can be used to genetically engineer Kluyveromyces to produce and secrete full-length antibodies or antibody fragments. The invention also provides methods for production and secretion of antibodies.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 30, 2024
    Assignee: Amyris, Inc.
    Inventor: Yoseph Tsegaye
  • Patent number: 11873479
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: January 16, 2024
    Assignee: SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
  • Patent number: 11873518
    Abstract: This disclosure relates to modified tryptophan synthase and more particularly to modified beta-subunits of tryptophan synthase. The disclosure further relates to cells expressing such modified subunits and methods of producing non-canonical amino acids.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: January 16, 2024
    Assignee: California Institute of Technology
    Inventors: David K. Romney, Javier Murciano Calles, Jori E. Wehrmuller
  • Patent number: 11866756
    Abstract: The embodiments of the present disclosure provides a method of co-producing erythritol and arabinose by using a xylose mother liquor, wherein an extract and a raffinate are obtained by separating the xylose mother liquor through a first chromatography, the extract is configured to prepare crystallized xylose, the raffinate and the liquid glucose or crystallized glucose are blended and erythritol is produced by using a Yarrowia lipolytica with high osmotolerant and a high conversion rate. erythritol crystals are obtained by centrifugation and crystallization first by using characteristics of low solubility degree and easy crystallization of the erythritol, the arabinose raffinate having a high content of arabinose is obtained by separating a centrifuged erythritol mother liquor through a second chromatography, and arabinose crystals are obtained based on the arabinose raffinate.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: January 9, 2024
    Assignee: ZHEJIANG HUAKANG PHARMACEUTICAL CO., LTD.
    Inventors: Aijuan Wu, Jiaxing Luo, Changhui Hu, Mingqian Yang, Chengjun Liao, Yi Zheng, Shuncheng Fang, Mian Li